Connect & Inspire

Share Your Story

Explore & Discover

Treatment & Care

Press Room

Subscribe

The Osteosarcoma Institute’s Year in Review

OSI Director Lee Helman, MD, looks at where we started, where we are, and where we’re going.

LATEST POSTS

New Horizons in the Treatment of Osteosarcoma

Dec 14, 2021 |

Authors, Dr. Lee Helman, Director of the Osteosarcoma Institute, and and Dr. Paul Meltzer, Chief of the Genetics Branch of the National Cancer Institute, go over where we are and where we need to go to improve outcomes for osteosarcoma in their Review Article published in the New England Journal of Medicine.

Connect & Inspire

Stories of inspiration, community, and survival 

A Second Mission to Overcome Osteosarcoma

A Second Mission to Overcome Osteosarcoma

Armond says family, students and connecting with others give him the courage and strength to fight osteosarcoma once again.
Read More
Two-time Osteosarcoma Survivor Never Let Cancer Define His Life

Two-time Osteosarcoma Survivor Never Let Cancer Define His Life

Carlos was diagnosed with osteosarcoma when he was 17 and again when he was 20. But, through it all, he never lost his passion for life.
Read More
After Rotationplasty Surgery, Jani Learns to Accept and Embrace Her Body

After Rotationplasty Surgery, Jani Learns to Accept and Embrace Her Body

This osteosarcoma survivor uses her cancer experience to help others love and accept their bodies as they are.
Read More
View More

Share Your Story

Fill out the form below to tell us about yourself. Sharing stories of osteosarcoma families helps us raise awareness and funds for much-needed research.

Share My Story

Gavin, Osteosarcoma Patient 

Explore & Discover

Stories of research, progress and exploration

The Osteosarcoma Institute’s Year in Review

The Osteosarcoma Institute’s Year in Review

OSI Director Lee Helman, MD, looks at where we started, where we are, and where we’re going.
Read More
Meet OSI’s New Scientific Project Manager

Meet OSI’s New Scientific Project Manager

OSI is thrilled to welcome Amy Lobner, MPH, CCRC, who brings with her a vast skill set rooted in clinical research and scientific development.
Read More
Meet Fernanda Arnaldez, MD, One of OSI’s Newest Strategic Advisory Board Members

Meet Fernanda Arnaldez, MD, One of OSI’s Newest Strategic Advisory Board Members

With more than 20 years of expertise studying rare diseases, Dr. Arnaldez is working to remove barriers to developing osteosarcoma treatments.
Read More
View More

Treatment and Care

No results found.

Press Room

OSI News & updates

A Phase II clinical trial funded by The Osteosarcoma Institute is now enrolling

This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment.
Read More

Researchers identify surface protein as a new osteosarcoma therapeutic target for antibody-drug conjugates

Novel approach paves the way for vast expansion in the number of drugs targeting osteosarcoma
Read More

The Osteosarcoma Institute to Fund Clinical Trial in Recurrent Osteosarcoma

The Osteosarcoma Institute (OSI) announced today that it has awarded a grant to Dana-Farber/Boston Children’s Cancer and Blood Disorders Center for a Phase II single arm study of olaparib (an FDA-approved PARP inhibitor) and ceralacertib/AZD6738 (an investigational ATR kinase inhibitor) in ...
Read More

Instagram

Before You Go

Sign-up for our newsletter and stay up-to-date about our fight against Osteosarcoma!

Sign Up
Translate »